Table S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337695

2024-01-01

Abstract:Table S2. PCR primers used in the experiments described in this manuscript are listed.

What problem does this paper attempt to address?

Table S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna B. Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337698

2024-01-01

Abstract:Table S1. Key reagents used in the experiments described in this manuscript are listed.
Figure S5 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337713.v1

2024-01-01

Abstract:Figure S5. PUMA was induced by p53 and required for necroptosis induction in LoVo cells treated with antimetabolites.
Figure S3 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna B. Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337719.v1

2024-01-01

Abstract:Figure S3. 5-FU and other antimetabolites induced necroptosis in p53-WT CRC cells expressing RIP3.
Figure S8 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337704

2024-01-01

Abstract:Figure S8. 5-FU-induced cell-surface translocation of calreticulin and DC phagocytosis of CRC cells are mediated by p53/PUMA/RIP3-dependent necroptosis.
Figure S4 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337716

2024-01-01

Abstract:Figure S4. Knockout or knockdown of RIP3, but not RIP1, suppressed necroptosis induced by 5-FU and other antimetabolites.
Figure S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna Beer-Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337725

2024-01-01

Abstract:Figure S1. No association was found between RIP1 and MLKL expression and CRC patient survival.
Figure S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Dongshi Chen,Kaylee Ermine,Yi-Jun Wang,Xiaojun Chen,Xinyan Lu,Peng Wang,Donna B. Stolz,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1535-7163.25337722.v1

2024-01-01

Abstract:Figure S2. Analysis of 30 anticancer drugs revealed that 5-FU and Gemcitabine induced necroptosis in LoVo cells.
Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25183960

2024-01-01

Abstract:Supplementary Table S4. Primers used for qPCR or generating knockout/knockdown constructs.
Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25191542

2024-01-01

Abstract:Supplementary Table S1. MAGeCK analysis of CRISPR screen results to identify regulator of immune evasion in orthotopic PDAC mouse models.
SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhaobo Liu,Lang Chen,Yimin Fang,Pingping Ma,Xiaochong Wu,Hao Kong,Wenting Liao,Jingping Hong,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25183972

2024-01-01

Abstract:Supplementary Figure S1. In vivo CRISPR screens to identify critical drivers of immune evasion; Supplementary Figure S2. Effects of Ripk2 depletion on tumor growth; Supplementary Figure S3. RIPK2 is overexpressed in human and mouse PDAC tissues; Supplementary Figure S4. Ablation of RIPK2 disrupts the desmoplastic TME; Supplementary Figure S5. RIPK2 modulates the immune profile and impairs anti-tumor T cell response; Supplementary Figure S6. RIPK2 restricts the activation and effector states of CD8+ T cells by impairing antigen presentation; Supplementary Figure S7. RIPK2 promotes MHC-I trafficking to lysosomes via NBR1; Supplementary Figure S8. RIPK2 ubiquitination promotes NBR1-mediated MHC-I degradation; Supplementary Figure S9. RIPK2 ablation potentiates the efficacy of PD-1 blockade; Supplementary Figure S10. Diagram illustrating RIPK2-mediated degradation of MHC I through autophagy–lysosome system.
Neuromedin U Receptor 1 Deletion Leads to Impaired Immunotherapy Response and High Malignancy in Colorectal Cancer

Yulai Zhou,Xiangyang Zhang,Yan Gao,Yinghui Peng,Ping Liu,Yihong Chen,Cao Guo,Gongping Deng,Yanhong Ouyang,Yan Zhang,Ying Han,Changjing Cai,Hong Shen,Le Gao,Shan Zeng

DOI: https://doi.org/10.1016/j.isci.2024.110318

IF: 5.8

2024-01-01

iScience

Abstract:Colorectal cancer (CRC) exhibits significant heterogeneity, impacting immunotherapy efficacy, particularly in immune desert subtypes. Neuromedin U receptor 1 (NMUR1) has been reported to perform a vital function in immunity and inflammation. Through comprehensive multi-omics analyses, we have systematically characterized NMUR1 across various tumors, assessing expression patterns, genetic alterations, prognostic significance, immune infiltration, and pathway associations at both the bulk sequencing and single-cell scales. Our findings demonstrate a positive correlation between NMUR1 and CD8+ T cell infiltration, with elevated NMUR1 levels in CD8+ T cells linked to improved immunotherapy outcomes in patients with CRC. Further, we have validated the NMUR1 expression signature in CRC cell lines and patient-derived tissues, revealing its interaction with key immune checkpoints, including lymphocyte activation gene 3 and cytotoxic T-lymphocyte-associated protein 4. Additionally, NMUR1 suppression enhances CRC cell proliferation and invasiveness. Our integrated analyses and experiments open new avenues for personalized immunotherapy strategies in CRC treatment.
Phosphodiesterase 4A Confers Resistance to PGE2-mediated Suppression in CD25+ /CD54+ NK Cells.

Ziqing Chen,Ying Yang,Shi Y. Neo,Hao Shi,Yi Chen,Arnika K. Wagner,Karin Larsson,Le Tong,Per-Johan Jakobsson,Evren Alici,Jing Wu,Yihai Cao,Kai Wang,Lisa L. Liu,Yumeng Mao,Dhifaf Sarhan,Andreas Lundqvist

DOI: https://doi.org/10.15252/embr.202051329

IF: 9.071

2021-01-01

EMBO Reports

Abstract:Inadequate persistence of tumor-infiltrating natural killer (NK) cells is associated with poor prognosis in cancer patients. The solid tumor microenvironment is characterized by the presence of immunosuppressive factors, including prostaglandin E2 (PGE2), that limit NK cell persistence. Here, we investigate if the modulation of the cytokine environment in lung cancer with IL-2 or IL-15 renders NK cells resistant to suppression by PGE2. Analyzing Cancer Genome Atlas (TCGA) data, we found that high NK cell gene signatures correlate with significantly improved overall survival in patients with high levels of the prostaglandin E synthase (PTGES). In vitro, IL-15, in contrast to IL-2, enriches for CD25+ /CD54+ NK cells with superior mTOR activity and increased expression of the cAMP hydrolyzing enzyme phosphodiesterase 4A (PDE4A). Consequently, this distinct population of NK cells maintains their function in the presence of PGE2 and shows an increased ability to infiltrate lung adenocarcinoma tumors in vitro and in vivo. Thus, strategies to enrich CD25+ /CD54+ NK cells for adoptive cell therapy should be considered.
Supplementary Table S2 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Wenhua Sang,Yiduo Zhou,Haiyan Chen,Chengxuan Yu,Lisi Dai,Zhongkun Liu,Lang Chen,Yimin Fang,Panpan Ma,Xiangji Wu,Hao Kong,Wenting Liao,Hong Jiang,Junbin Qian,Da Wang,Yun-Hua Liu

DOI: https://doi.org/10.1158/2159-8290.25191539

2024-01-01

Abstract:Supplementary Table S2. Detailed information of human pancreatic tissue array.
Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419831

2023-01-01

Abstract:Supplementary Table S1. Primers for qRT-PCR and MSP
Supplementary Table S1 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase Is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Yong Li,Shunqun Luo,Ruihua Ma,Jing Liu,Pingwei Xu,Huafeng Zhang,Ke Tang,Jingwei Ma,Yi Zhang,Xiaoyu Liang,Yanling Sun,Tiantian Ji,Ning Wang,Bo Huang

DOI: https://doi.org/10.1158/0008-5472.22409990.v1

2023-01-01

Abstract:Supplementary Table S1. List of RT-PCR primers used.
Metadata Record for the Manuscript: Knockout of Immunotherapy Prognostic Marker Genes Eliminates the Effect of the Anti-Pd-1 Treatment

Ning Yang,Fansen Ji,Likun Cheng,Jiangbo Lu,Sun Xiao-feng,Xiao Lin,Xun Lan

DOI: https://doi.org/10.6084/m9.figshare.14034656

2021-01-01

Abstract:SummaryThis metadata record provides details of the data supporting the claims of the related manuscript: “Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment ”. The related study sought to increase the statistical power of detecting genes related to patient survival by combining information from different studies involving various immunotherapies. Type of data: RNA sequencing, clinical data Subject of data: Mus musculus: Mouse B6. Malt1-/-, sourced from Ruefli-Brasse et al., 2003; Mouse B6. Malt1fl/fl, sourced from Cheng et al., 2019; Mouse B6. Dectin3-/-, sourced from Zhu et al. 2013. Sample size: RNA-seq data of 19 mice tumour tissues (WT mice received IgG: n=6; WT mice received anti-PD-1: n=6; KO mice received IgG: n=3; KO mice received anti-PD-1: n=4) Data access The RNA sequencing data are openly available in the Gene Expression Omnibus (GEO) repository via the following accession: https://identifiers.org/geo:GSE158056. The clinical data and genotype data of TCGA tumour samples are contained in the files ‘Table S4_ImmunotherapyPrognosticMarker Genes_list.xlsx’, ‘TCGA_clinical_rawdata.rar’, ‘dNdS_value_AllCancerType.tar.gz’, ‘Table S1_raw_clincaldata_TCGA.xlsx’, ‘immunotherapy-SNP-103.txt’, shared together with this metadata record. The tumour growth in WT and KO mice are contained in the files ‘Clec4d_WT-KO_TumorSize.pzf’, ‘Malt1_WT-KO-TumorSize.pzfx’, ‘MeanFluorescenceIntensity.pzfx’, shared together with this metadata record. The gene expression tables of TCGA tumour samples are contained in the files ‘EBPlusPlusAdjustPANCAN_IlluminaHiSeq_RNASeqV2-v2.geneExp.tsv.gz’, ‘TCGA_pancancer.FractionCorrection_logqq.exp.txt.gz’, ‘TCGA_pancancer.MutationCorrection_logqq.exp.txt.gz’, shared together with this metadata record. In addition to being available via the related publication, Supplementary Tables 1-6 are also available via this data record.Corresponding author(s) for this study Xun Lan, Tel: 86-10-62770517; Fax: 86-10-62791875; E-mail: xlan@tsinghua.edu.cn. Xin Lin, Tel: 86-10-62796319; Fax: 86-10-62794262; E-mail: linxin307@tsinghua.edu.cn.
The BH3-only Protein, PUMA, is Involved in Oxaliplatin-Induced Apoptosis in Colon Cancer Cells

Xinyiny Wang,Ming Li,Jide Wang,Chung-Man Yeung,Hongquan Zhang,Hsiang-fu Kung,Bo Jiang,Marie Chia-mi Lin

DOI: https://doi.org/10.1016/j.bcp.2006.02.011

IF: 6.1

2006-01-01

Biochemical Pharmacology

Abstract:Oxaliplatin, the first line chemotherapeutic of colon cancer, induces damage to tumors via induction of apoptosis. PUMA (p53 up-regulate modulator of apoptosis) is an important pro-apoptotic member of Bcl-2 family and regulated mainly by p53. Here we investigated the role of PUMA in oxalipaltin-induced apoptosis and the potential mechanism. We showed that oxaliplatin-induced PUMA expression in a time- and dose-dependent manner and suppression of PUMA expression by stable transfecting anti-sense PUMA plasmid decreased oxaliplatin-induced apoptosis in colon cancer cells. By abrogating the function of p53, we further demonstrated that the induction was p53-independent. We also found that oxaliplatin could inactivate ERK and suppression of ERK activity by its specific inhibitor (PD98059), and dominant negative plasmid (DN-MEK1) enhanced the oxaliplatin-induced PUMA expression and apoptosis in a p53-independent manner. Taken together, our data suggest that PUMA plays an important role in oxaliplatin-induced apoptosis and the induction could be both p53-dependent and p53-independent. Moreover, PUMA expression and apoptosis in oxaliplatin-treated colon cancer cells could be regulated partly by ERK inactivation. Identification of the molecular components involved in regulating the cellular sensitivity to oxaliplatin may provide potential targets for development of novel compounds that may be useful in enhancement of oxaliplatin cytotoxicity in p53 deficient colon cancer.
Contribution of Rip3 and Mlkl to Immunogenic Cell Death Signaling in Cancer Chemotherapy

Heng Yang,Yuting Ma,Guo Chen,Heng Zhou,Takahiro Yamazaki,Christophe Klein,Federico Pietrocola,Erika Vacchelli,Sylvie Souquere,Allan Sauvat,Laurence Zitvogel,Oliver Kepp,Guido Kroemer

DOI: https://doi.org/10.1080/2162402x.2016.1149673

2016-01-01

OncoImmunology

Abstract:Chemotherapy can reinstate anticancer immunosurveillance through inducing tumor immunogenic cell death (ICD). Here, we show that anthracyclines and oxaliplatin can trigger necroptosis in murine cancer cell lines expressing receptor-interacting serine-threonine kinase 3 (RIP3) and mixed lineage kinase domain-like (MLKL). Necroptotic cells featured biochemical hallmarks of ICD and stimulated anticancer immune responses in vivo. Chemotherapy normally killed Rip3(-/-) and Mlkl(-/-) tumor cells and normally induced caspase-3 activation in such cells, yet was unable to reduce their growth in vivo. RIP3 or MLKL deficiency abolished the capacity of dying cancer cells to elicit an immune response. This could be attributed to reduced release of ATP and high mobility group box 1 (HMGB1) by RIP3 and MLKL-deficient cells. Measures designed to compensate for deficient ATP and HMGB1 signaling restored the chemotherapeutic response of Rip3(-/-) and Mlkl(-/-) cancers. Altogether, these results suggest that RIP3 and MLKL can contribute to ICD signaling and tumor immunogenicity.
Supplementary Figure 5 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers

Luxi Chen,Yi Yuan,Shreya Kar,Madhu M. Kanchi,Suruchi Arora,Ji E. Kim,Pei F. Koh,Einas Yousef,Ramar P. Samy,Muthu K. Shanmugam,Tuan Z. Tan,Sung W. Shin,Frank Arfuso,Han M. Shen,Henry Yang,Boon C. Goh,Joo I. Park,Louis Gaboury,Peter E. Lobie,Gautam Sethi,Lina H.K. Lim,Alan P. Kumar

DOI: https://doi.org/10.1158/1535-7163.22509307

2023-01-01

Abstract:<p>Supplementary Figure 5: PPARγ ligand-induced expression of ANXA1 interacts with RIP1 blocking RIP1-NEMO interaction leading to deubiquitination of RIP1.</p>
Abstract 2534: Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance

Kaylee Ermine,Dongshi Chen,Xinyan Lu,Jian Yu,Lin Zhang

DOI: https://doi.org/10.1158/1538-7445.am2023-2534

IF: 11.2

2023-04-04

Cancer Research

Abstract:Abstract Colorectal cancer (CRC) is a leading cause of cancer related deaths in the United States. CRC patients are often treated with the chemotherapeutic drug 5-fluorouracil (5-FU), but resistance often occurs. It is well-established that 5-FU induces apoptosis in cancer cells, but apoptosis inhibition does not block the anticancer effect of 5-FU, suggesting a role of non-apoptotic cell death. Necroptosis is a regulated form of necrosis controlled by Receptor-Interacting Protein kinase 1 (RIP1), RIP3, and Mixed Lineage Kinase domain-Like (MLKL), and its role in anticancer therapy remains unclear. TCGA RNAseq data show that RIP3 is significantly downregulated in primary CRC tumors, which is correlated with worse outcomes. RIP3 downregulation also occurs in established CRC cell lines and is associated with decreased 5-FU sensitivity. Therefore, we hypothesize that necroptosis may play a critical role in anticancer therapy and that restoring defective necroptosis may enhance therapeutic sensitivity. Our studies show that RIP3-expressing (RIP3+) CRC cells undergo both apoptosis and necroptosis in response to 5-FU. As expected, knock-out of RIP3 in RIP3+ CRC cells resulted in decreased 5-FU sensitivity, as well as abrogated necroptosis induction. Additionally, stable restoration of RIP3 in RIP3-silenced (RIP3-) CRC cells appeared to enhance 5-FU response, under conditions where apoptosis was inhibited. Furthermore, we explored alternative ways to induce necroptosis in RIP3-silenced cells. Together, our results suggest that necroptosis plays an important role in 5-FU-induced cell death in CRC. These results provide novel insights into the role of necroptosis in anticancer therapy in CRC, which could be used for development of improved therapies and personalized medicine based on RIP3 status. Citation Format: Kaylee Ermine, Dongshi Chen, Xinyan Lu, Jian Yu, Lin Zhang. Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2534.

oncology

Table S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Table S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S5 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S3 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S8 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S4 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S1 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Figure S2 from PUMA/RIP3 Mediates Chemotherapy Response Via Necroptosis and Local Immune Activation in Colorectal Cancer

Supplementary Table S4 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Supplementary Table S1 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

SUPPLEMENTARY DATA FIGURES from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Neuromedin U Receptor 1 Deletion Leads to Impaired Immunotherapy Response and High Malignancy in Colorectal Cancer

Phosphodiesterase 4A Confers Resistance to PGE2-mediated Suppression in CD25+ /CD54+ NK Cells.

Supplementary Table S2 from Receptor-interacting Protein Kinase 2 is an Immunotherapy Target in Pancreatic Cancer

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Table S1 from Upregulation of Cytosolic Phosphoenolpyruvate Carboxykinase Is a Critical Metabolic Event in Melanoma Cells That Repopulate Tumors

Metadata Record for the Manuscript: Knockout of Immunotherapy Prognostic Marker Genes Eliminates the Effect of the Anti-Pd-1 Treatment

The BH3-only Protein, PUMA, is Involved in Oxaliplatin-Induced Apoptosis in Colon Cancer Cells

Contribution of Rip3 and Mlkl to Immunogenic Cell Death Signaling in Cancer Chemotherapy

Supplementary Figure 5 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers

Abstract 2534: Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance